TTR and Familial transthyretin-related amyloidosis: An early report on the treatment of Transthyretin amyloidosis by LNP encapsulating Cas9 mRNA and transthyretin (TTR)-targeted sgRNA has already entered the third clinical phase (NTLA-2001), which was the first in vivo CRISPR gene editing therapy approved for advanced clinical development [21].